Almac adds simple solutions to bridge the gap between clinical and commercial packaging

Almac adds simple solutions to bridge the gap between clinical and commercial packaging         

Addressing client demand to ease the transition between clinical and commercial launch for blister products, Almac a leading provider in clinical and commercial contract packaging to the global Pharmaceutical and Biotech industries has added new blistering technology at their US commercial packaging facility in Audubon, PA

The Klockner EAS blister line can produce a range of blister formats processing both thermoform and coldform materials.  This provides simple solutions for client packaging projects requiring low volume runs for evaluation of different packaging material combinations and cost effective stability packaging.

David Moore, Director of Operations at the Audubon facility explains "Almac are offering seamless services from clinical supply, packaging development / design and stability testing to final commercial pack from its two Pennsylvania sites. Clients can now easily transition from the clinical blister presentation though various development packs, with Almac providing all the associated stability services".

The addition of a further blister line complements the already impressive array of clinical and commercial packaging capabilities of blistering, bottling, walleting and vial /ampoule labelling available at Almac.

For more information on Almac's US packaging capabilities, please contact

[email protected]

Almac will be exhibiting at Pharma Packaging & Labeling Philadelphia 26 – 27 Feb 2014 and Interphex New York 18 – 20 March 2014.

Notes to Editors

The Almac Group provides a broad range of services from R&Dbiomarker discovery and developmentAPI manufactureformulation developmentclinical trial supply and IXRS®technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.  The company employs over 3,500 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.

For media enquiries, please contact Tristan Jervis on +44 (0) 207 203 6740 or e-mail: [email protected].  

 

Tristan Jervis

Managing Partner

 

Description: Description: Description: Description: Description: Description: Description: Description: Description: DF logo

Holborn Gate, 26 Southampton Buildings

London WC2A 1BP

 

Telephone: +44 (0)207 203 6742

Direct: +44 (0)207 203 6740

E-mail: [email protected]

www.defacto.com

 

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.